Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov enrollment closed early-phase tilt small index

Metastatic NSCLC: early-phase trial registry

A small indexed set (1 trial) with no open enrollment listed right now.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · none currently recruiting · #11,370 of 28,707 conditions by registered trial count

Metastatic NSCLC: 1 US clinical trial tracked, none currently recruiting.

Metastatic NSCLC is the subject of 1 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Nanobiotix, running 1 of these trials.

Enrollment posture brief

Registry condition metastatic-nsclc

OPEN 0 | RECR 0% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Metastatic NSCLC (this)0%
Open-enrollment share among volume-matched conditions near Metastatic NSCLC

Metastatic NSCLC has no open enrollment in this registry pull (1 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Metastatic NSCLC on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Metastatic NSCLC is recruiting below its size-band peers.

    0 of 1 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11

Phase Distribution

PhaseTrial count
Phase 1 1

Top Sponsors

Nanobiotix 1 trials

Named interventions

Most-linked intervention names on Metastatic NSCLC records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

NBTXR3 Drug
1 trials
SABR Radiation
1 trials
Nivolumab Drug
1 trials
Pembrolizumab Drug
1 trials

US sites by state

Facility locations filed on Metastatic NSCLC trials. A trial with sites in several states counts in each.

South Dakota 1 trials
Pennsylvania 1 trials
Ohio 1 trials
New York 1 trials
New Mexico 1 trials
North Carolina 1 trials
Michigan 1 trials
Maryland 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Metastatic NSCLC page

1 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • No Metastatic NSCLC trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Nanobiotix sponsors the most Metastatic NSCLC trials on record, review their full trial history before evaluating a specific study. See Nanobiotix's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Metastatic NSCLC condition card totals 1 registered trials; most-linked intervention NBTXR3; top US site state South Dakota. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.